Results 1 to 10 of about 33,699 (271)

Unique Research for Developing a Full Factorial Design Evaluated Liquid Chromatography Technique for Estimating Budesonide and Formoterol Fumarate Dihydrate in the Presence of Specified and Degradation Impurities in Dry Powder Inhalation. [PDF]

Biomed Chromatogr
A simple LC method has been developed and validated for estimating budesonide (epimer B + A) and formoterol fumarate dihydrate in dry powder inhalation. The development results of this study make it very significant.
Bandaru LGR, Konduru N, Kowtharapu LP, Gundla R, Kanuparthy PR, Katari NK.   +5 more
europepmc   +3 more sources

Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial [PDF]

Therapeutic Advances in Respiratory Disease, 2021
Background: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose levels ...
Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin Jenkins, Patrick Darken, Magnus Aurivillius, Paul Dorinsky   +7 more
doaj   +4 more sources

Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study. [PDF]

Adv Ther
Chronic obstructive pulmonary disease (COPD) often results in progressive airflow limitation and is a major cause of morbidity, mortality, and healthcare resource utilization (HCRU). Single-inhaler triple therapy with budesonide/glycopyrronium/formoterol
Alcázar-Navarrete B, Figueira-Gonçalves JM, Corregidor-García C, Fitas E, Sánchez-Covisa J, ORESTES group.   +5 more
europepmc   +4 more sources

Real-Life Efficacy of Single-Inhaler Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate in Persistent COPD Users: A Retrospective Database Study. [PDF]

Biomedicines
Background/Objective: Single-inhaler triple therapy (SITT) with budesonide/formoterol/glycopyrronium (B/F/G) is an option for COPD patients with frequent exacerbations.
Sposato B, Lacerenza LG, Croce S, Petrucci E, Fabbrini V, Giannini L, Baratta P, Cresti A, Ricci A, Micheletto C, Perrella A, Alonzi V, Serafini A, Scalese M.   +13 more
europepmc   +4 more sources

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids [PDF]

Respiratory Research, 2021
Background For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to use functional
Maarten van den Berge, Jan De Backer, Cedric Van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius   +7 more
doaj   +6 more sources

Green Assessment of Sensitive Spectrofluorimetric Methods for Simultaneous Estimation of Formoterol Fumarate and Fluticasone Propionate Using a Micelle-Mediated Approach. [PDF]

J Fluoresc
Highly sensitive spectrofluorimetric methods were developed for the quantitative estimation of formoterol fumarate dihydrate (FFD) and fluticasone propionate (FP) in both authentic raw materials and marketed dosage forms using a micellar-enhanced ...
Adawy HA, Hegazy MA, Saad SS, Boltia SA.
europepmc   +4 more sources

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS [PDF]

International Journal of COPD
Shigeo Muro,1 Munehiro Seki,2 John R Hurst,3 David Petullo,4 Jonathan Marshall,5 Karin Bowen,4 Patrick F Darken,4 Elizabeth A Duncan,6 Ayman Megally,4 Mehul Patel5 1Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 2AstraZeneca K ...
Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M   +9 more
doaj   +3 more sources

Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history [PDF]

Respiratory Research
Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis ...
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel   +8 more
doaj   +3 more sources

Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report. [PDF]

Front Med (Lausanne)
Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma.
Maiorano A, Lupia C, Montenegro N, Neri G, Bruni A, Garofalo E, Longhini F, Crimi C, Maglio A, Vatrella A, Pelaia G, Pelaia C.   +11 more
europepmc   +4 more sources

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma [PDF]

Pharmacology Research & Perspectives, 2022
The single‐inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been evaluated.
Piotr Kuna, Joanna Jerzynska, Matteo Martini, Andrea Vele, Irene Barneschi, Fabrizia Mariotti, George Georges, Giorgia Ciurlia   +7 more
doaj   +4 more sources